Clinical trial · Interventional
Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC
A Randomized, Prospective Study of the Efficacy and Safety of the 1st Treatment in Advanced Central NSCLC by PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Bronchoscopic Microwave Intervention
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Effect Increased | — | UNRESOLVED | — |
| Safety Issues | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy | Drug | — | UNRESOLVED |
| bronchoscopic microwave intervention | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
- description
- anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
- interventionNames
- Drug: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
- type
- EXPERIMENTAL
- label
- combined with bronchoscopic microwave intervention
- description
- anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
- interventionNames
- Procedure: bronchoscopic microwave intervention
- Drug: anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy
Primary outcomes (2)
- measure
- objective response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * advanced central non-small cell lung cancer patients, untreated, tolerating bronchoscopy Exclusion Criteria: * contraindications to tracheoscopy, chemotherapy, and immunotherapy
References
Publications (0)
Data not yet available